Back to Archived News
Lipid Sciences Broadens Intellectual Property Portfolio With Two New Patents
Wednesday, May 07, 2008
Lipid Sciences, Inc. (Nasdaq: LIPD) announced the issuance of two strategic patents from the U.S. Patent and Trademark Office. The first of these patents, "Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content," covers the Company's HDL Selective Delipidation technology. HDL Selective Delipidation modifies naturally occurring HDL resulting in the creation of a substantially more effective scavenger form of HDL. This "energized" HDL has been shown to dramatically increase reverse cholesterol transport, the body's process for removing cholesterol from plaque in the cardiovascular system.
Results of the Company's 'first in man' HDL Selective Delipidation clinical trial to evaluate safety and feasibility of its Plasma Delipidation System in subjects with prior Acute Coronary Syndrome, indicated a strong trend of effectiveness. The intravascular ultrasound measurements in the 28-patient study group showed that the average total atheroma volume in the target coronary arteries decreased by 5.31% in the treatment group versus a 1.33% increase in the placebo group. The effect on the average of the 10 mm most-diseased arterial segments was a 7.34% decrease for the treated group as compared to a 2.10% decrease in the placebo group. While not statistically significant due to the small number of patients enrolled, these results are, nevertheless, a strong indication of the potential of this therapy to reverse coronary artery disease with only seven weeks of treatment.
The second patent, "A Method of Treating Cancer Cells to Create a Modified Cancer Cell that Provokes an Immunogenic Response," covers the ability of the Company's delipidation process to modify cancer cells and create a cancer cell antigen -- demonstrating the potential of this novel process to develop a range of cancer vaccines.
Dr. S. Lewis Meyer, President and Chief Executive Officer of Lipid Sciences, commented, "The issuance of these important new patents for Lipid Sciences is a clear validation of our intellectual property strategy. We have established a strong intellectual property position supporting a wide range of applications of our targeted lipid removal technology. Patent protection for HDL Selective Delipidation creates significant, potential value for this breakthrough cardiovascular disease therapy. The issuance of a patent related to the treatment of cancer, while not the focus of the Company's current development programs, represents a major therapeutic and preventive opportunity addressing the second leading cause of death in the U.S. Cancer vaccines are emerging as the next frontier in the global fight against cancer."
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Mimetic Peptides and HDL Selective Delipidation) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, SARS, and influenza. In addition, Lipid Sciences believes that this Viral Immunotherapy platform also has applicability to a wide range of viruses impacting animal health -- a diverse market with diseases affecting both food and companion animals.
This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: our inability to obtain adequate funds; our technologies not proving to be safe or effective; our inability to obtain regulatory approval of our technologies, which are only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; our reliance on key suppliers to provide the material necessary to conduct successful pre-clinical and clinical studies; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; and our dependence on key personnel.
This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.
Back to Archived News